Affiliation:
1. Department of Population Health Sciences Weill Cornell Medical College New York New York USA
2. Division of Health Policy and Management University of Minnesota Minneapolis Minnesota USA
3. Minnesota Department of Health Saint Paul Minnesota USA
4. Department of Health Care Policy Harvard Medical School Boston Massachusetts USA
Abstract
AbstractObjectiveTo compare direct‐to‐consumer (DTC) telemedicine and in‐person visits in rates of testing, follow‐up health care use, and quality for urinary tract infections (UTIs) and sinusitis.Data SourceThe Minnesota All Payer Claims Data provided 2008–2015 administrative claims data.Study DesignUsing a difference‐in‐differences approach, we compared episodes of care for UTIs and sinusitis among enrollees of health plans introducing coverage for DTC telemedicine relative to those without DTC telemedicine coverage. Primary outcomes included number of laboratory tests, antibiotics filled, office and outpatient visits, emergency department (ED) visits, and standardized spending, based on standardized prices of health services.Data CollectionThe study sample included non‐elderly enrollees of commercial health insurance plans. We constructed 30‐day episodes of care initiated by a DTC telemedicine or in‐person visit.Principal FindingsThe UTI and sinusitis samples were comprised of 215,134 and 624,630 episodes of care, respectively. Following the introduction of coverage for DTC telemedicine, 15.7% of UTI episodes and 8.9% of sinusitis episodes were initiated with DTC telemedicine. Compared to episodes without coverage for DTC telemedicine, UTI episodes with coverage had 0.25 fewer lab tests (95% CI: −0.33, −0.18; p < 0.001), lower standardized spending for the first UTI visit (−$11.18 [95% CI: ‐$21.62, −$0.75]; p < 0.05), and no change in office and outpatient visits, ED visits, antibiotics filled, or standardized medical spending. Sinusitis episodes with coverage for DTC telemedicine had fewer antibiotics filled (−0.08 [95% CI: −0.14, −0.01]; p < 0.05) and a very small increase in ED visits (0.001 [95% CI: 0.001, 0.010]; p < 0.05), but no change in lab tests, office and outpatient visits, or standardized medical spending.ConclusionsAmong commercially insured patients, coverage of DTC telemedicine was associated with reductions in antibiotics for sinusitis and laboratory tests for UTI without changes in downstream total office and outpatient visits or changes in ED visits.
Funder
Agency for Healthcare Research and Quality
Reference36 articles.
1. PiferR.Covid‐19 spurs tripling in Teladoc visits to 2.8 m full‐year outlook hiked again. Healthcare Dive. Published July 29 2020. Accessed February 15 2022.https://www.healthcaredive.com/news/covid‐19‐spurs‐tripling‐in‐teladoc‐visits‐to‐28m‐full‐year‐outlook‐hiked/582546/
2. Prescriptions on Demand
3. Population-Level Estimates Of Telemedicine Service Provision Using An All-Payer Claims Database
4. Direct-to-Consumer Telemedicine
5. Teladoc Health's revenue & visits grew ever higher in Q2 2020. MobiHealthNews.https://www.mobihealthnews.com/news/teladoc-healths-revenue-visits-grew-ever-higher-q2-2020